Humana’s 40% Discount Suggests Market Underestimates Membership-Driven Recovery Setup

The market is playing a high-stakes game of expectations versus reality for these two MA giants. For Humana, the stock is trading at a deep discount, suggesting the worst is still priced in. For UnitedHealth, the pain is more recent, but the market may be overreacting to a temporary stumble.

Humana's stock sits 40.6% below its 52-week high, a gap that persists even after management's March reaffirmation of at least $9.00 in adjusted EPS. That disconnect is the core tension. The market is treating the $3.5 billion Stars headwind as a permanent discount, yet the company's underlying business shows strength, with individual MA membership growing 25% in 2026. The setup is clear: Wall Street expects a beat-and-raise from Humana when it reports on April 29, but the stock's steep decline suggests few believe the company can deliver on its recovery story.

UnitedHealth's situation is different, but the pressure is real. The stock has dropped nearly 17% in 2026 and is off 15.36% year-to-date, pressured by weaker guidance and ongoing MA strain. The market is pricing in a narrow miss for its April 21 report, with consensus expecting adjusted EPS of $6.69, down 8% year-over-year. Yet, the stock's decline has pushed it below the price Berkshire Hathaway paid, sparking debate about whether this is a buying opportunity or the start of a longer reset.

The critical quarter is now. Both companies face a reality check. For Humana, the question is whether its guidance can close the expectation gap. For UnitedHealth, it's whether the company can show its cost-saving plans are working fast enough to offset the MA headwinds. The market's verdict will hinge on which narrative-structural collapse or temporary earnings miss-turns out to be the better priced-in story.

Earnings Reality: What Was Priced In vs. What Happened

The recent earnings prints tell a story of expectations met, but not rewarded. For Humana, the beat was real, but the market had already moved on. The company's Q3 2025 EPS of $3.24 beat the consensus estimate of $2.95 by $0.29. Yet, the stock's 52-week high was set before that quarter. This is the classic "sell the news" dynamic. The beat was priced in, or perhaps the market was already focused on the looming Stars headwind. The result was a lack of follow-through; the positive print didn't close the expectation gap.

UnitedHealth's situation was a clear miss on the headline number, and the market punished it swiftly. In its Q4 2025 report, a $2.88 billion pre-tax charge collapsed GAAP earnings to just $0.01 per share. While adjusted EPS hit the estimate, the GAAP collapse was a stark reality check that the market had not fully priced in. Shares fell 19.61% that day, confirming the punishment for a report that revealed deeper financial strain than expected.

The key divergence lies in what's driving the stock now. Humana's positive trend-a 25% growth in individual MA membership in 2026-is not reflected in the price. Management is targeting a doubling of individual MA pre-tax margins, a fundamental recovery story. But the market is treating this as a future promise, not a current catalyst. The stock's steep discount suggests investors are waiting for that margin improvement to materialize in the numbers, not just the membership growth.

For UnitedHealth, the market is punishing the present reality of a massive charge and weak guidance. The expectation gap here is that the company is still in a costly reset phase, and the market is demanding faster proof of the turnaround. The earnings print confirmed the pain, but the stock's decline shows the market is pricing in a longer, more painful path to recovery than some may have hoped.

The Forward Look: Guidance, Catalysts, and What to Watch

The coming quarters are all about closing the expectation gap. For Humana, the market has already seen the beat; now it needs to see the guidance. The company's March reaffirmation of at least $9.00 adjusted EPS is a key data point, confirming the $3.5 billion Stars headwind is fully priced in. The stock's steep discount suggests few believe the promised recovery. The critical test is whether management can offer any upward revision or, more importantly, upgrade its tone on the path to doubling individual MA margins. The March 10 Leerink Partners conference will be the first major signal post-reaffirmation. Any commentary hinting at a faster margin recovery or a stronger 2028 earnings power could spark a re-rating. Without it, the stock may remain stuck in the trough.

For UnitedHealth, the upcoming Q1 report on April 21 is the critical test. The market is pricing in a narrow miss, but the real question is whether the company can show its cost-saving plans are working fast enough to offset the MA strain. Investors need to see if higher medical costs and tighter Medicare Advantage rules are starting to ease. The whisper number here is likely for a beat on the headline adjusted EPS of $6.69, but the stock's fate will hinge on management commentary about the trajectory of medical costs and the durability of its savings. Options traders are pricing in a move of about 9% in either direction, highlighting the high stakes.

The key catalyst for both is the same: management commentary on Medicare Advantage margins and membership growth. Any deviation from the whisper number will move the stock. For Humana, the market is waiting for evidence that its 25% membership growth is translating into margin recovery. For UnitedHealth, it's about proving that its $330 price target from Raymond James is still on track. The expectation gap will narrow only when the forward view aligns with the recovery story.